Humacyte (HUMA) Files Form 144 to Sell 549,360 Shares via UBS

Rhea-AI Filing Summary

Form 144 notice for HUMA (Humacyte, Inc.) reporting a proposed sale of common stock. The filer plans to sell 549,360 shares through UBS Financial Services Inc. on or about 08/18/2025, with an aggregate market value of $1,002,928.10. The company has 158,372,173 shares outstanding. The securities were originally acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares when the company went public via SPAC; the original acquired amount shown is 18,930,004 shares with payment listed as cash. No securities were reported sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Rule 144 sale notice: modest block listed for sale relative to total shares outstanding; appears procedural, not a disclosed material event.

The filing is a standard Form 144 reporting a proposed sale of 549,360 common shares via UBS with an aggregate market value of $1.00M. Compared with the issuer's reported 158.37M shares outstanding, the block represents roughly 0.35% of outstanding shares, suggesting limited supply-side impact. The acquisition history shows these shares originated from a pre-public investment converted at SPAC closing on 08/26/2021. No sales in the past three months are reported. From a securities-flow perspective, this notice is informational and does not, by itself, signal a material corporate development.

Corporate Governance Expert

TL;DR: Filing is procedural and includes the seller's standard attestation about undisclosed material information.

The Form 144 includes the usual signature/attestation language confirming the filer does not possess undisclosed material adverse information and notes the acquisition origin (early-stage investor in AHAC converted at IPO). The filing does not disclose any insider trading plan or 10b5-1 adoption date. Because the document contains no executive departures, related-party transactions beyond the conversion note, or governance actions, it appears to be a routine liquidity notice rather than a governance event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	549360	1002928.1	158372173	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/26/2021	EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC.	HUMACYTE INC			18930004	08/26/2021	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does Humacyte (HUMA) plan to sell according to this Form 144?

The filer intends to sell 549,360 shares of Humacyte common stock through UBS Financial Services Inc.

What is the reported aggregate market value of the proposed HUMA sale?

The aggregate market value is reported as $1,002,928.10.

When were the shares being sold originally acquired?

The shares were acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares at the SPAC-related public listing.

How many Humacyte shares are outstanding per this filing?

The filing reports 158,372,173 shares outstanding.

Does the Form 144 report any securities sold by the filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.